Q - Brad Canino
Analyst
Guggenheim
Equibles does not estimate personal net worth.
About Q - Brad Canino
Q - Brad Canino is recorded as Analyst at Guggenheim. Q - Brad Canino has spoken on 6 earnings calls and 1 other investor event across 6 companies, most recently for Celcuity Inc. on August 13, 2026. Those appearances were for Summit Therapeutics Inc. (SMMT), Celcuity Inc. (CELC), Kymera Therapeutics, Inc. (KYMR), Syndax Pharmaceuticals Inc (SNDX), Bicara Therapeutics Inc. (BCAX) and 1 other company. The companies whose calls Q - Brad Canino spoke on are classified in the Healthcare sector.
Q - Brad Canino on recent calls
“I'm actually wondering about a different cancer setting, because I know one of your competitors in the space is doing a lot of work in endometrial cancer. And I'm wondering how you think about that as an opportunity for Get-A-Tolseb.”
“And thanks to Jared for the collaboration over the past five years. I've definitely learned a lot from our conversations. My question is about moving STAT6 to the late-stage development phase.”
“One, just any quantification you can provide on the duration of treatment increasing, either numerical or some estimation of a relative increase the DOT saw. I'm just trying to judge the magnitude of increase.”
“The question for me is around the regional enrollment in H3.”
“At ASCO, maybe just to drill into one of the doses, the lower 750 mg, which wasn't selected for the phase three. So, how do you look at that as really being able to support the TGF beta hypothesis given the exposure and coverage that it provides?”
Affiliation history
-
Guggenheim
Analyst
Transcript header (unverified)
Current
Company network
Celcuity Inc.
CELC
Biotechnology · Healthcare
1 appearance
Latest appearance 2026-08-13
View calls and events